Novartis Shareholders OK Spinoff Of $9.6B Sandoz Unit
Swiss pharmaceutical giant Novartis AG said Friday that its shareholders have approved plans to spin off its Sandoz division, thus forming a standalone publicly traded generic drugs company....To view the full article, register now.
Already a subscriber? Click here to view full article